title: Feasibility of home infusion and self-administration of nanofiltered C1 esterase inhibitor for routine prophylaxis in patients with hereditary angioedema and characterization of a training and support program.
abstract: Hereditary angioedema (HAE) is a rare, chronic disease of C1 inhibitor deficiency. Study researchers evaluated the prevalence of home and self-administration of nanofiltered, human-derived C1 esterase inhibitor infusions and the implementation of a nursing training and support program. Home administration rate increased from 49.0% to 75.8%. The percentage who self-administered increased from 20.3% to 43.9%. Doses per week averaged 1.85 at home compared with 1.40 in infusion centers and physicians' offices. Patients required an average of 5 visits to be trained. Self-administration is a viable, feasible option in the management of HAE, which is facilitated by a nurse-managed training and support program.
authors.affiliation: Specialty Pharmacy Nursing Network, Inc, Sarasota, Florida (Ms Gregory); and ViroPharma Incorporated, Exton, Pennsylvania (Mr Corrigan and Drs Landmesser and Mariano). Cherylann Gregory, BSN, RN, is the founder of Specialty Pharmacy Nursing Network, Inc. She received her BSN from Madonna University and has 20 years of experience in oncology and specialty pharmacy therapies. Over the past 10 years, she developed and implemented a specialty therapy nursing model to service patients with rare, chronic disorders. Ladonna M. Landmesser, PharmD, is a medical communications specialist at ViroPharma Incorporated. She received her doctor of pharmacy degree from the University of the Sciences in Philadelphia and previously was employed at Lankenau Medical Center, where she gained 5 years of experience preparing parenteral medications and admixtures. Larry Corrigan, MBA, BA, is a business operations manager for ViroPharma Incorporated. He received his BA from the University of Pittsburgh and also holds an MBA from Pennsylvania State University. With more than 12 years of experience in the pharmaceutical industry, his primary expertise is in commercial operations and data analytics. David Mariano, PharmD, is the senior director of publications at ViroPharma Incorporated. He graduated from Temple University with a doctor of pharmacy degree and practiced clinically at Thomas Jefferson Hospital for 11 years. With 12 years of experience in the pharmaceutical industry, his primary expertise is in pharmacovigilance, publications, and medical education.
authors.forename: Cherylann
authors.initials: C
authors.lastname: Gregory
authors.forename: Ladonna M
authors.initials: LM
authors.lastname: Landmesser
authors.forename: Larry
authors.initials: L
authors.lastname: Corrigan
authors.forename: David
authors.initials: D
authors.lastname: Mariano
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D054179:Angioedemas, Hereditary / Q000188:drug therapy*; D002648:Child; D050718:Complement C1 Inhibitor Protein / Q000008:administration & dosage / Q000627:therapeutic use*; D005240:Feasibility Studies; D005260:Female; D006699:Home Care Services; D006801:Humans; D008297:Male; D008875:Middle Aged; D012646:Self Administration; D055815:Young Adult
chemical_list: D050718:Complement C1 Inhibitor Protein